[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354918-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354918-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","inhibition-of-galnt7-suppresses-cell-proliferation-and-invasiveness-while-elevating-cell-apoptosis-via-the-inactivation-of-the-akt-pathway-in-non-small-cell-lung-cancer","Inhibition of GALNT7 suppresses cell proliferation and invasiveness while elevating cell apoptosis via the inactivation of the AKT pathway in non-small cell lung cancer","","Objective: Polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7) contributes to cancer development and progression; this study evaluates how GALNT7 inhibition affects non-small cell lung cancer (NSCLC) cell proliferation, apoptosis, and invasiveness, and whether these effects are mediated by the AKT pathway. Methods: si-GALNT7 or si-NC was transfected into A549 and NCI-H1650 cells, followed by treatment with the AKT activator 740 Y-P, with or without transfection. Results: si-GALNT7 reduced proliferation, increased apoptosis, lowered invasive cell numbers, and decreased phosphorylated AKT/AKT; 740 Y-P reversed these effects. Conclusion: GALNT7 inhibition suppresses NSCLC proliferation and invasiveness while increasing apoptosis by inactivating AKT.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/inhibition-of-galnt7-suppresses-cell-proliferation-and-invasiveness-while-elevating-cell-apoptosis-via-the-inactivation-of-the-akt-pathway-in-non-small-cell-lung-cancer/354918/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/inhibition-of-galnt7-suppresses-cell-proliferation-and-invasiveness-while-elevating-cell-apoptosis-via-the-inactivation-of-the-akt-pathway-in-non-small-cell-lung-cancer/354918.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main aim of inhibiting GALNT7 in NSCLC cells?","Question",{"text":63,"@type":64},"To determine whether GALNT7 inhibition suppresses NSCLC cell proliferation and invasiveness, increases apoptosis, and whether these effects are mediated through the AKT pathway.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the experiments designed to test GALNT7 and AKT involvement?",{"text":68,"@type":64},"A549 and NCI-H1650 cells were transfected with si-GALNT7 or si-NC, then treated with the AKT activator 740 Y-P with or without siRNA transfection.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes were observed after GALNT7 inhibition?",{"text":72,"@type":64},"Cell proliferation decreased, apoptosis increased, invasive cell numbers decreased, and phosphorylated AKT/AKT expression was lower compared with si-NC.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354918,1790795040,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Lung cancer  \nInhibition of GALNT7 suppresses cell proliferation and invasiveness while elevating cell apoptosis via the inactivation of the AKT pathway in non-small cell lung cancer  \nYijian Zhou  , Yichen Shi, Jianwei Zhou, Xintao Zhu, Zhiheng Wei, Yiwen Zhang   \nTo cite: Zhou Y, Shi Y, Zhou J, et al. Inhibition of GALNT7 suppresses cell proliferation and invasiveness while elevating cell apoptosis via the inactivation of the AKT pathway in non-small cell lung cancer. BMJ Open Respir Res 2026;13:e003560 . doi:10.1136/ bmjresp-2025-003560  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi](https://doi). org/10.1136/bmjresp-2025- 003560) .  \nReceived 26 June 2025 Accepted 29 December 2025  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nDepartment of Radiology, Shanghai Chest Hospital,  \nShanghai Jiao Tong University School of Medicine, Shanghai, China  \nCorrespondence to  \nDr Yiwen Zhang; [zyw_radiol@163.com](zyw_radiol@163.com)  \nABSTRACT  \nObjective Polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7) is a glycopeptide transferase which is closely involved in the development and progression of cancer. This study aimed to investigate the effects of GALNT7 inhibition on non-small cell lung cancer (NSCLC) cell proliferation, apoptosis and invasiveness and to determine whether these effects are mediated by the protein kinase B (AKT) pathway.  \nMethods Negative control small interfering RNA (siRNA)(si-NC) and siRNA targeting GALNT7 (si-GALNT7) were transfected into A549 and NCI-H1650 cells. Afterwards, the AKT activator ‘740 Y-P’ was added to treat the cells with or without siRNA transfection.  \nResults Cell proliferation was reduced after si-GALNT7 transfection compared with si-NC transfection at 24 hours, 48 hours and 72 hours in A549 cells, and at 48 hours and 72 hours in NCI-H1650 cells. Furthermore, the cell apoptosis rate was increased, but the cell invasive number was decreased after si-GALNT7 transfection compared with si-NC transfection in A549 cells and NCI-H1650 cells. Phosphorylated (p)-AKT/AKT expression was lower after siGALNT7 transfection compared with si-NC transfection in A549 cells and NCI-H1650 cells. Worth noting, the effects of si-GALNT7 transfection on the above-mentioned cell proliferation, apoptosis and invasiveness were repressed by the addition of 740 Y-P in A549 cells and NCI-H1650 cells.  \nConclusion GALNT7 inhibition suppresses NSCLC cell proliferation and invasiveness while increasing apoptosis through inactivation of the AKT pathway.  \nINTRODUCTION  \nNon-small cell lung cancer (NSCLC) is the predominant type of lung cancer and has high incidence and mortality rates.1 2 Targeted therapy is one of the cornerstones for NSCLC treatment: for resectable cases, it can be applied as neoadjuvant and/or adjuvant treatment; for advanced or recurrent cases, it can be applied as first-line or salvage treatment.3–5  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7) is a glycopeptide transferase that is closely involved in the development and progression of cancer, but related information is scarce in nonsmall cell lung cancer.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ GALNT7 inhibition suppresses non-small cell lung cancer cell proliferation and invasiveness while increasing apoptosis through inactivating the protein kinase B pathway.\u003Cbr>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY |\n\n⇒ This study provides some evidence supporting GALNT7 as a potential target for non-small cell lung cancer treatment for the first time.  \nIn addition to well-known targets such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), whose target drugs have been widely applied for NSCLC treatment,6–8 an increasing number of potential targets have been n","cbCaigXZ1CZPm0QA","https://ap.wps.com/l/cbCaigXZ1CZPm0QA","pdf",4329278,"English","# Abstract\n# Introduction\n## What is already known on this topic\n## What this study adds\n## How this study might affect research, practice or policy","[{\"question\":\"What is the main aim of inhibiting GALNT7 in NSCLC cells?\",\"answer\":\"To determine whether GALNT7 inhibition suppresses NSCLC cell proliferation and invasiveness, increases apoptosis, and whether these effects are mediated through the AKT pathway.\"},{\"question\":\"How were the experiments designed to test GALNT7 and AKT involvement?\",\"answer\":\"A549 and NCI-H1650 cells were transfected with si-GALNT7 or si-NC, then treated with the AKT activator 740 Y-P with or without siRNA transfection.\"},{\"question\":\"What outcomes were observed after GALNT7 inhibition?\",\"answer\":\"Cell proliferation decreased, apoptosis increased, invasive cell numbers decreased, and phosphorylated AKT/AKT expression was lower compared with si-NC.\"}]","Inhibition of GALNT7 suppresses cell proliferation and invasiveness while elevating cell apoptosis via the inactivation of the AKT pathway in non-small cell lung cancer | PDF",1790114822,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10975f0cebeaa3337abdd6a22d4670f0.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69c03832734ea0c93ce8b31fb1b540ef.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abb466f19589863a921487ec84d5666f.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/817ea6b8797e9ff7d6520f4d95a30114.webp",980,1306]